کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3285482 | 1209230 | 2006 | 9 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Staging Hepatocellular Carcinoma by a Novel Scoring System (BALAD Score) Based on Serum Markers
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
BCLCAFP-L3AICJISDCPTACEJapan Integrated Stagingtranscatheter arterial chemoembolization - chemoembolization شریانی transcatheterHCC - HCCα-fetoprotein - α-فتو پروتئینMRI - امآرآی یا تصویرسازی تشدید مغناطیسیAFP - تست AFP یا آلفا فیتو پروتئینMagnetic resonance imaging - تصویربرداری رزونانس مغناطیسیcomputed tomography - توموگرافی کامپیوتری یا سی تی اسکن یا مقطعنگاری رایانهایLAT - سالCancer of the Liver Italian Program - سرطان برنامه ایتالیایی کبدUltrasonography - سونوگرافی Akaike Information Criteria - معیارهای اطلاعات Akaikedes-γ-carboxy prothrombin - پروترومبین دیس-γ-کاربوکسیHepatocellular carcinoma - کارسینوم هپاتوسلولار(کارسینوم سلولهای استخوانی)Barcelona Clinic Liver Cancer - کلینیک بارسلون سرطان کبدClip - کلیپ
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
بیماریهای گوارشی
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
Background & Aims: Previously proposed staging systems for hepatocellular carcinoma (HCC) involve clinical, imaging, or pathologic factors in the evaluation. We established and validated a novel staging system for HCC that is based on simply serum markers. Methods: The new scoring system is based on 5 serum markers: bilirubin, albumin, Lens culinaris agglutinin-reactive α-fetoprotein (AFP-L3), α-fetoprotein (AFP), and des-γ-carboxy prothrombin (DCP) and thus is termed the BALAD score. The system was validated in 2600 HCC patients from 5 institutions. The power of our system to predict patient survival and its discriminative ability were compared with those of previously reported staging systems. Results: The best tumor marker cutoff values were 400 ng/dL for AFP, 15% for AFP-L3, and 100 milli-arbitrary unit/mL for DCP. The patients were classified into 6 categories on the basis of 5 laboratory values. The categories reflected patient survival well. The discriminative ability was comparable to that of previously reported staging systems. Conclusions: The new staging system for HCC combining serum albumin, serum bilirubin, and 3 tumor markers predicts patient outcomes with excellent discriminative ability. The system is easy to use and objective. In addition, stage can be evaluated with the use of only 1 serum sample. It also allows global comparison of patients with HCC or comparison of patients from different time periods with the same standard.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Clinical Gastroenterology and Hepatology - Volume 4, Issue 12, December 2006, Pages 1528-1536
Journal: Clinical Gastroenterology and Hepatology - Volume 4, Issue 12, December 2006, Pages 1528-1536
نویسندگان
Hidenori Toyoda, Takashi Kumada, Yukio Osaki, Hiroko Oka, Fumihiro Urano, Masatoshi Kudo, Takashi Matsunaga,